Oncostatin M pathway plays a major role in the renal acute phase response

American Journal of Physiology - Renal Physiology

Volumn 296, Issue 4, 2009, Pages

  Luyckx, Valerie A ^a   Cairo, Lucas V ^a   Compston, Catharine A ^a   Wai, Lee Phan ^a   Mueller, Thomas F ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Inflammatory response; Ischemia and reperfusion injury

Indexed keywords

FIBRINOGEN; FIBRINOGEN BETA; INTERLEUKIN 6 RECEPTOR; LEUKEMIA INHIBITORY FACTOR; LIPOPOLYSACCHARIDE BINDING PROTEIN; ONCOSTATIN M; ONCOSTATIN M RECEPTOR BETA; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ACUTE PHASE RESPONSE; ARTICLE; BIOPSY; CADAVER DONOR; DISEASE SEVERITY; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL CULTURE; HUMAN TISSUE; KIDNEY; KIDNEY DONOR; KIDNEY INJURY; KIDNEY PARENCHYMA; KIDNEY PROXIMAL TUBULE; LIVING DONOR; NEPHRECTOMY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

EID: 65949107063     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.90633.2008     Document Type: Article

References (53)

1. Avihingsanon Y, Ma N, Pavlakis M, Chon WJ, Uknis ME, Monaco AP, Ferran C, Stillman I, Schachter AD, Mottley C, Zheng XX, Strom TB. On the intraoperative molecular status of renal allografts after vascular reperfusion and clinical outcomes. J Am Soc Nephrol 16: 1542-1548, 2005. (Pubitemid 41716461)
2. Baumann H, Wang Y, Richards CD, Jones CA, Black TA, Gross KW. Endotoxin-induced renal inflammatory response. Oncostatin M as a major mediator of suppressed renin expression. J Biol Chem 275: 22014-22019, 2000. (Pubitemid 30621777)
3. Bedi S, Vidyasagar A, Djamali A. Epithelial-to-mesenchymal transition and chronic allograft tubulointerstitial fibrosis. Transplant Rev (Orlando) 22: 1-5, 2008. (Pubitemid 350131582)
4. Blanchard F, Wang Y, Kinzie E, Duplomb L, Godard A, Baumann H. Oncostatin M regulates the synthesis and turnover of gp130, leukemia inhibitory factor receptor alpha, and oncostatin M receptor beta by distinct mechanisms. J Biol Chem 276: 47038-47045, 2001. (Pubitemid 37373078)
5. Boros P, Bromberg JS. New cellular and molecular immune pathways in ischemia/reperfusion injury. Am J Transplant 6: 652-658, 2006. (Pubitemid 43345001)
6. Brown TJ, Rowe JM, Liu JW, Shoyab M. Regulation of IL-6 expression by oncostatin M. J Immunol 147: 2175-2180, 1991.
7. Camargo CA Jr, Madden JF, Gao W, Selvan RS, Clavien PA. Interleukin-6 protects liver against warm ischemia/reperfusion injury and promotes hepatocyte proliferation in the rodent. Hepatology 26: 1513-1520, 1997. (Pubitemid 27520017)
8. Cavaillon JM, Annane D. Compartmentalization of the inflammatory response in sepsis and SIRS. J Endotoxin Res 12: 151-170, 2006. (Pubitemid 47487521)
9. Chen SH, Benveniste EN. Oncostatin M: a pleiotropic cytokine in the central nervous system. Cytokine Growth Factor Rev 15: 379-391, 2004.
10. Duan HO, Simpson-Haidaris PJ. Functional analysis of interleukin 6 response elements (IL-6REs) on the human gamma-fibrinogen promoter: binding of hepatic Stat3 correlates negatively with transactivation potential of type II IL-6REs. J Biol Chem 278: 41270-41281, 2003.
11. Fischer M, Goldschmitt J, Peschel C, Brakenhoff JP, Kallen KJ, Wollmer A, Grotzinger J, Rose-John S. I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat Biotechnol 15: 142-145, 1997. (Pubitemid 27081778)
12. Fischer P, Hilfiker-Kleiner D. Role of gp130-mediated signalling pathways in the heart and its impact on potential therapeutic aspects. Br J Pharmacol 153, Suppl 1: S414-S427, 2008.
13. Gabay C, Kushner I. Acute phase proteins and other systemic responses to inflammation. N Engl J Med 340: 448-454, 1999. (Pubitemid 29084777)
14. Gomez-Lechon MJ. Oncostatin M: signal transduction and biological activity. Life Sci 65: 2019-2030, 1999.
15. Grigoryev DN, Liu M, Hassoun HT, Cheadle C, Barnes KC, Rabb H. The local and systemic inflammatory transcriptome after acute kidney injury. J Am Soc Nephrol 19: 547-558, 2008.
16. Guillet C, Fourcin M, Chevalier S, Pouplard A, Gascan H. ELISA detection of circulating levels of LIF, OSM, and CNTF in septic shock. Ann NY Acad Sci 762: 407-409, 1995.
17. Gwechenberger M, Moertl D, Pacher R, Huelsmann M. Oncostatin M in myocardial ischemia/reperfusion injury may regulate tissue repair. Croat Med J 45: 149-157, 2004. (Pubitemid 38724577)
18. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374: 1-20, 2003. (Pubitemid 37046923)
19. Hertig A, Anglicheau D, Verine J, Pallet N, Touzot M, Ancel PY, Mesnard L, Brousse N, Baugey E, Glotz D, Legendre C, Rondeau E, Xu-Dubois YC. Early epithelial phenotypic changes predict graft fibrosis. J Am Soc Nephrol 19: 1584-1591, 2008.
20. Hertig A, Verine J, Mougenot B, Jouanneau C, Ouali N, Sebe P, Glotz D, Ancel PY, Rondeau E, Xu-Dubois YC. Risk factors for early epithelial to mesenchymal transition in renal grafts. Am J Transplant 6:2937-2946, 2006.
21. Hurst SM, McLoughlin RM, Monslow J, Owens S, Morgan L, Fuller GM, Topley N, Jones SA. Secretion of oncostatin M by infiltrating neutrophils: regulation of IL-6 and chemokine expression in human mesothelial cells. J Immunol 169: 5244-5251, 2002. (Pubitemid 35217196)
22. Kushner I. The phenomenon of the acute phase response. Ann NY Acad Sci 389: 39-48, 1982. (Pubitemid 12013176)
23. Lenz A, Franklin GA, Cheadle WG. Systemic inflammation after trauma. Injury 38: 1336-1345, 2007. (Pubitemid 350192404)
24. Lieberthal W, Nigam SK. Acute renal failure. I. Relative importance of proximal vs. distal tubular injury. Am J Physiol Renal Physiol 275: F623-F631, 1998. (Pubitemid 28536332)
25. Medzhitov R. Origin and physiological roles of inflammation. Nature 454: 428-435, 2008.
26. Mirshahi F, Vasse M, Vincent L, Trochon V, Pourtau J, Vannier JP, Li H, Soria J, Soria C. Fibrinogen: a vascular risk factor, why? Contributing effect of oncostatin M on both fibrinogen biosynthesis by hepatocytes and participation in atherothrombotic risk related to modifications of endothelial cells. Ann NY Acad Sci 936: 621-624, 2001. (Pubitemid 32613947)
27. Modur V, Feldhaus MJ, Weyrich AS, Jicha DL, Prescott SM, Zimmerman GA, McIntyre TM. Oncostatin M is a proinflammatory mediator. In vivo effects correlate with endothelial cell expression of inflammatory cytokines and adhesion molecules. J Clin Invest 100: 158-168, 1997. (Pubitemid 27311254)
28. Mueller TF, Reeve J, Jhangri GS, Mengel M, Jacaj Z, Cairo L, Obeidat M, Todd G, Moore R, Famulski KS, Cruz J, Wishart D, Meng C, Sis B, Solez K, Kaplan B, Halloran PF. The transcriptome of the implant biopsy identifies donor kidneys at increased risk of delayed graft function. Am J Transplant 8: 78-85, 2008.
29. Nakamura K, Nonaka H, Saito H, Tanaka M, Miyajima A. Hepatocyte proliferation and tissue remodeling is impaired after liver injury in oncostatin M receptor knockout mice. Hepatology 39: 635-644, 2004. (Pubitemid 38337643)
30. Nankivell BJ, Chapman JR. Chronic allograft nephropathy: current concepts and future directions. Transplantation 81: 643-654, 2006.
31. Nechemia-Arbely Y, Barkan D, Pizov G, Shriki A, Rose-John S, Galun E, Axelrod JH. IL-6/IL-6R axis plays a critical role in acute kidney injury. J Am Soc Nephrol 19: 1106-1115, 2008.
32. Nightingale J, Patel S, Suzuki N, Buxton R, Takagi KI, Suzuki J, Sumi Y, Imaizumi A, Mason RM, Zhang Z. Oncostatin M, a cytokine released by activated mononuclear cells, induces epithelial cell-myofibroblast transdifferentiation via Jak/Stat pathway activation. J Am Soc Nephrol 15: 21-32, 2004. (Pubitemid 38020694)
33. Nijboer WN, Schuurs TA, van der Hoeven JA, Fekken S, Wiersema-Buist J, Leuvenink HG, Hofker S, Homan van der Heide JJ, van Son WJ, Ploeg RJ. Effect of brain death on gene expression and tissue activation in human donor kidneys. Transplantation 78: 978-986, 2004. (Pubitemid 39391858)
34. Ojo AO, Wolfe RA, Held PJ, Port FK, Schmouder RL. Delayed graft function: risk factors and implications for renal allograft survival. Transplantation 63: 968-974, 1997.
35. Patel NS, Chatterjee PK, Di Paola R, Mazzon E, Britti D, De Sarro A, Cuzzocrea S, Thiemermann C. Endogenous interleukin-6 enhances the renal injury, dysfunction, and inflammation caused by ischemia/reperfusion. J Pharmacol Exp Ther 312: 1170-1178, 2005. (Pubitemid 41487065)
36. Piquet-Pellorce C, Grey L, Mereau A, Heath JK. Are LIF and related cytokines functionally equivalent? Exp Cell Res 213: 340-347, 1994. (Pubitemid 24259478)
37. Plenz G, Eschert H, Erren M, Wichter T, Bohm M, Flesch M, Scheld HH, Deng MC. The interleukin-6/interleukin-6-receptor system is activated in donor hearts. J Am Coll Cardiol 39: 1508-1512, 2002. (Pubitemid 34439068)
38. Pollack V, Sarkozi R, Banki Z, Feifel E, Wehn S, Gstraunthaler G, Stoiber H, Mayer G, Montesano R, Strutz F, Schramek H. Oncostatin M-induced effects on EMT in human proximal tubular cells: differential role of ERK signaling. Am J Physiol Renal Physiol 293: F1714-F1726, 2007. (Pubitemid 46227092)
39. Pratschke J, Tullius SG, Neuhaus P. Brain death associated ischemia/reperfusion injury. Ann Transplant 9: 78-80, 2004.
40. Pratschke J, Wilhelm MJ, Kusaka M, Basker M, Cooper DK, Hancock WW, Tilney NL. Brain death and its influence on donor organ quality and outcome after transplantation. Transplantation 67: 343-348, 1999. (Pubitemid 29094001)
41. Richards CD, Brown TJ, Shoyab M, Baumann H, Gauldie J. Recombinant oncostatin M stimulates the production of acute phase proteins in HepG2 cells and rat primary hepatocytes in vitro. J Immunol 148: 1731-1736, 1992.
42. Schlondorff DO. Overview of factors contributing to the pathophysiology of progressive renal disease. Kidney Int 74: 860-866, 2008.
43. Sharples EJ, Patel N, Brown P, Stewart K, Mota-Philipe H, Sheaff M, Kieswich J, Allen D, Harwood S, Raftery M, Thiemermann C, Yaqoob MM. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 15: 2115-2124, 2004. (Pubitemid 38130644)
44. Siewert E, Dietrich CG, Lammert F, Heinrich PC, Matern S, Gartung C, Geier A. Interleukin-6 regulates hepatic transporters during acute-phase response. Biochem Biophys Res Commun 322: 232-238, 2004. (Pubitemid 39093860)
45. Skrabal CA, Thompson LO, Potapov EV, Southard RE, Joyce DL, Youker KA, Noon GP, Loebe M. Organ-specific regulation of proinflammatory molecules in heart, lung, and kidney following brain death. J Surg Res 123: 118-125, 2005. (Pubitemid 40094653)
46. Tamura S, Morikawa Y, Tanaka M, Miyajima A, Senba E. Developmental expression pattern of oncostatin M receptor beta in mice. Mech Dev 115: 127-131, 2002. (Pubitemid 34615676)
47. Tanaka M, Miyajima A. Oncostatin M, a multifunctional cytokine. Rev Physiol Biochem Pharmacol 149: 39-52, 2003.
48. Vitalone MJ, O'Connell PJ, Jimenez-Vera E, Yuksel A, Wavamunno M, Fung CL, Chapman JR, Nankivell BJ. Epithelial-to-mesenchymal transition in early transplant tubulointerstitial damage. J Am Soc Nephrol 19: 1571-1583, 2008.
49. Wahab NA, Mason RM. A critical look at growth factors and epithelial-to-mesenchymal transition in the adult kidney. Interrelationships between growth factors that regulate EMT in the adult kidney. Nephron Exp Nephrol 104: e129-e134, 2006.
50. Wang H, Ma S. The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome. Am J Emerg Med 26: 711-715, 2008.
51. Winsauer G, de Martin R. Resolution of inflammation: intracellular feedback loops in the endothelium. Thromb Haemost 97: 364-369, 2007. (Pubitemid 46437797)
52. Yarlagadda SG, Klein CL, Jani A. Long-term renal outcomes after delayed graft function. Adv Chronic Kidney Dis 15: 248-256, 2008.
53. Yoshino J, Monkawa T, Tsuji M, Hayashi M, Saruta T. Leukemia inhibitory factor is involved in tubular regeneration after experimental acute renal failure. J Am Soc Nephrol 14: 3090-3101, 2003. (Pubitemid 37509287)